Keyword: Omalizumab , Asthma , Immunoglobulin E , Interleukin-5 , Treatment Outcome , Interleukin-13 , Th2 Cells , Molecular Targeted Therapy , Anti-IgE Antibodies , Mepolizumab pp.1121-1128
Published Date 2016/12/1
DOI https://doi.org/10.15106/J00974.2017097368

©Nankodo Co., Ltd., 2016

基本情報

電子版ISSN 2432-9452 印刷版ISSN 0022-1961 南江堂

関連文献

もっと見る

文献を共有